Nurix Therapeutics (NRIX) Income from Non-Controlling Interests (2024 - 2026)
Nurix Therapeutics' (NRIX) quarterly Income from Non-Controlling Interests came in at -$49000.0 in Q1 2026, down 164.47% year-on-year from $76000.0 in Q1 2025, and up 80.08% on a QoQ basis from -$246000.0 in Q2 2025.
Nurix Therapeutics (NRIX) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$49000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nurix Therapeutics | 2.64 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -49,000.00 |
| May 31, 2025 | -246,000.00 |
| Feb 28, 2025 | 76,000.00 |
| May 31, 2024 | 215,000.00 |
| Feb 29, 2024 | 305,000.00 |